ClinicalTrials.gg
Active, not recruitingNCT06072183Tranquillo 2Updated Nov 12, 2026

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

A Phase 3 interventional study of Ritlecitinib and Ritlecitinib in Stable Nonsegmental Vitiligo and Active Nonsegmental Vitiligo, sponsored by Pfizer. Active, not recruiting at 229 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Updated Nov 12, 202640 sites added40 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,571
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies in Vitiligo with a site in United States — 14 open to participants now, 24 under way, 7 of them phase 3. Vitiligo · United States.

Enrollment
Largest of 68
1,571 · median 37
Started
2023
with 9 others
Phase 3
12 of 80
1 open now
Primary completion
2027-07
later than 14 of 23 live
Registered
61st of 80
by date
Lead sponsor
4 of 80
Pfizer

Among the 80 studies in Vitiligo with a site in United States, this one has the largest enrollment of the 68 interventional ones that give a count, is one of 10 that started in 2023, is one of 12 in phase 3, reaches primary completion later than 14 of the 23 other live ones, and was the 61st registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

14 of the 80 studies in Vitiligo with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Vitiligo with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental vitiligo. Vitiligo causes white patches on your skin when the cells that give your skin color are destroyed. Nonsegmental means that it can affect both sides of the body such as both knees and both hands.

Ritlecitinib has been tested in earlier clinical studies and has a favorable safety profile. At present there are no approved medications taken by mouth to treat nonsegmental vitiligo.

This study is seeking participants who:

  • Are 18 years of age or older.
  • are confirmed to have nonsegmental vitiligo for at least 3 months.
  • Are willing to stop all other treatments that they may be taking for vitiligo.

In this study participants will be chosen by chance, like drawing names out of a hat to receive 1 of 3 treatments:

•Part I where two different amounts of ritlecitinib (50 mg and 100 mg) are taken once daily. It will be compared to placebo. Placebo is a dummy capsule. It doesn't have any medicine used in the study.

Participants receiving placebo who have not responded to treatment after 52 weeks will be given 100 milligrams or 50 milligrams of ritlecitinib for the remaining 52 weeks of the study.

  • In Part II, participants will only receive 100 milligrams of ritlecitinib. About 1000 participants will take part in Part I and around 450 in Part II globally. The study will compare the experiences of people receiving ritlecitinib to those of the people who do not. This will help see if ritlecitinib is safe and effective.

People in Part I will be in this study for about 26 months and people in Part II will be in this study for about 14 months. During the study, participants in part I will need to visit the study site at least 17 times. In part II, participants will visit at least 11 times.

Participants will undergo various tests and procedures such as:

  • vitiligo rating,
  • physical examinations,
  • hearing tests,
  • blood tests,
  • x-ray,
  • ECG,
  • photographs of areas with vitiligo. Participants will be asked to complete questionnaires about their vitiligo.
Read the detailed description

Study B7981080 is a Phase 3 randomized, double-blind, multicenter study with a 52-week placebo-controlled period (Part Ia) followed by a double-blind 52-week extension period (Part Ib) that includes randomized dose-up/down titration and a de novo 52-week non-randomized open-label cohort (Part II), investigating the efficacy, safety, and tolerability of ritlecitinib 100 mg QD and 50 mg QD compared with placebo in adult participants with nonsegmental active or stable vitiligo

03

Conditions studied

  • Stable Nonsegmental Vitiligo
  • Active Nonsegmental Vitiligo

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants aged 18 years (or the minimum age of consent in accordance with local regulations) or older (no upper age limit) at Screening.

    • Meeting reproductive criteria for female participants.

    Disease Characteristics:

  2. Eligible participants must have at both Screening and BL:

    • A clinical diagnosis of nonsegmental vitiligo for at least 3 months; and
    • BSA involvement 4% to 60% inclusive, excluding involvements at palms of the hands, soles of the feet, or dorsal aspect of the feet and
    • BSA ≥0.5% involvement on the face. Face is defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. Face will not include scalp, ears, neck, or surface area of the lips, but will include the nose and the eyelids; and
    • F-VASI ≥0.5 and T-VASI ≥3; and
    • Either active or stable nonsegmental vitiligo at Screening and BL visits. All participants who do not have the features of active vitiligo (defined below) will be classified as having stable disease.

    Active vitiligo is defined as:

    Participants will be classified as having active vitiligo based on the presence of at least one active lesion at BL defined as one of the following:

    • New/extending lesions(s) in the 3 months prior to Screening visit (confirmed by photographs or medical record);
    • Confetti-like lesion(s); Confetti-like depigmentation is characterized by the presence of numerous 1-mm to 5-mm depigmented macules in clusters;
    • Trichrome lesion(s); Trichrome lesions have a hypopigmented zone of varying width between normal and completely depigmented skin, resulting in 3 different hues of skin;
    • Koebner phenomenon/phenomena (excluding Type 1 [history based on isomorphic reaction]). The Koebner phenomenon manifests as depigmentation at sites of trauma, usually in a linear arrangement.

    Stable vitiligo is defined as:

    • Participants will be classified as having stable vitiligo based on an absence of signs of active disease. All participants who do not have the features of active vitiligo (defined above) will be classified as having stable disease.

    Eligibility is determined at Screening and Baseline based on the resulting scores from the local in-person reads of F-VASI, T-VASI, and BSA.

  3. Additional inclusion criteria are:

    • If receiving concomitant medications for any reason other than vitiligo, participant must be on a stable regimen, which is defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) prior to Day 1. Participant must be willing to stay on a stable regimen during the duration of the study.
    • Must agree to stop all other treatments for vitiligo from Screening through the final follow-up visit.

Exclusion criteria

Exclusion Criteria:

Medical Conditions:

  1. Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

    • Any psychiatric condition including recent or active suicidal ideation or behavior that meets defined criteria.
  2. Medical conditions pertaining to vitiligo and other diseases/conditions affecting the skin:

    • Participants that have other types of vitiligo that do not meet criteria for active or stable vitiligo as noted in inclusion criteria (including but not limited to segmental vitiligo and mixed vitiligo).
    • Currently have active forms of other hypopigmentation (including but not limited to Vogt-Koyanagi-Harada disease, -induced hypopigmentation [melanoma and mycosis fungoides], post-inflammatory hypopigmentation, pityriasis alba [minor manifestation of atopic dermatitis], senile leukoderma [age-related depigmentation], chemical/drug-induced leukoderma, ataxia telangiectasia, tuberous sclerosis, melasma, and congenital hypopigmentation disorder including piebaldism, Waardenburg syndrome, hypomelanosis of Ito, incontinentia pigmenti, dyschromatosis symmetrica hereditarian, xeroderma pigmentosum, and nevus depigmentosus). NOTE: Coexistence of halo nevus/nevi (also known as Sutton nevus/nevi) is permitted.
    • Currently have active forms of inflammatory skin disease(s) or evidence of skin conditions (for example, but not limited to morphea, discoid lupus, leprosy, syphilis, psoriasis, seborrheic dermatitis) at the time of the Screening or BL Visit that in the opinion of the investigator would interfere with evaluation of vitiligo or response to treatment.
    • Leukotrichia in more than 33% of the face surface area affected with vitiligo lesions or leukotrichia in more than 33% of the total body surface area affected with vitiligo lesions.
    • Have a superficial skin infection within 2 weeks prior to first dose on Day 1. NOTE: participants may be rescreened after the infection resolves.
  3. General Infection History:

    • Have a history of systemic infection requiring hospitalization, parenteral antimicrobial, antiviral (including biologic treatment), antiparasitic, antiprotozoal, or antifungal therapy, or as otherwise judged by the investigator within 6 months prior to Day 1.
    • Have active acute or chronic infection requiring treatment with oral antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 4 weeks prior to Day 1. NOTE: participants may be rescreened after the infection resolves.
    • Evidence or history of untreated, currently treated or inadequately treated active or latent infection with Mycobacterium tuberculosis.
  4. Specific Viral Infection History:

    • History (single episode) of disseminated HZ or disseminated herpes simplex or recurrent (more than one episode of) localized, dermatomal HZ.
    • Infected with or : all participants will undergo screening for HBV and HBC for eligibility.
    • Participants who are positive for HCVAb and HCV RNA will not be eligible for this study.
    • Have a known immunodeficiency disorder (including positive serology for at screening) or a first-degree relative with a hereditary immunodeficiency.
  5. Other Medical Conditions:

    • Current or recent history of clinically significant severe, progressive, or uncontrolled renal (including but not limited to active renal disease or recent kidney stones), hepatic, hematological, gastrointestinal, metabolic, endocrine (eg, untreated hypovitaminosis D or hypothyroidism), pulmonary, cardiovascular, psychiatric, immunologic/rheumatologic or neurologic disease; or have any other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or product administration, or interfere with the interpretation of study results; or in the opinion of the investigator or Pfizer (or designee), the participant is inappropriate for entry into this study, or unwilling/unable to comply with study procedures and lifestyle requirements.
    • History of severe allergic or anaphylactoid reaction to any kinase inhibitor or a known allergy/ to any component (including ) of the study intervention.
    • Have hearing loss with progression over the previous 5 years, sudden hearing loss, or middle or inner ear disease such as otitis media, cholesteatoma, Meniere's disease, labyrinthitis, or other auditory condition that is considered current, fluctuating, or progressive.
    • Have a history of any lymphoproliferative disorder such as EBV-related lymphoproliferative disorder, history of lymphoma, history of leukemia, or signs and symptoms suggestive of current lymphatic or lymphoid disease.
    • Abnormal findings on the Screening chest imaging (eg, chest x-ray). Chest imaging may be performed up to 12 weeks prior to screening. Documentation of the official reading must be located and available in the source documentation.
    • Long Syndrome, a family history of Long QT Syndrome, or a history of TdP.
    • Have any malignancies or have a history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
    • Significant trauma or major surgery within 1 month of the first dose of study drug or considered in imminent need for surgery or with elective surgery scheduled to occur during the study.

    Prior/Concomitant Therapy:

  6. Have received any of the prohibited treatment regimens specified.

    Prior/Concurrent Clinical Study Experience:

  7. Previous administration with an investigational drug or vaccine that do not affect vitiligo within 4 weeks of Day 1 [Baseline] or within 5 half-lives, whichever is longer.

    Diagnostic Assessments:

    Any of the following abnormalities in clinical laboratory tests at Screening, as assessed by the study-specific laboratory and, if deemed necessary, confirmed by a single repeat:

  8. Renal impairment
  9. Hepatic dysfunction
  10. Other laboratory abnormalities
  11. Standard 12-lead that demonstrates clinically relevant abnormalities

    Other Exclusion Criteria:

  12. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,571 participants (actual)

Study arms

  • Experimental
    Arm 1- Ritlecitinib 100 milligrams (mg)

    Randomized to Ritlecitinib 100 mg QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status.

    Drug: Ritlecitinib

  • Experimental
    Arm 2- Ritlecitinib 50mg

    Randomized to Ritlecitinib 50 mg QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status.

    Drug: Ritlecitinib

  • Placebo comparator
    Arm 3- Placebo

    Randomized to Placebo QD for 52 weeks before progressing into the up/down titration extension period, rerandomized according to responder status.

    Drug: Placebo

  • Experimental
    Arm 4- Ritlecitinib 100mg

    Non-randomized open-label Ritlecitinib 100mg QD for 52 weeks.

    Drug: Ritlecitinib

Interventions

06

What researchers measure

Primary outcomes

  1. US only Co-Primary Endpoints: Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52 and Total body Vitiligo Area Scoring Index 50 (T-VASI50) at Week 52

    Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline) and T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline)

    Time frame: 52 Weeks

  2. Global (Other than US): Response based on Facial Vitiligo Area Scoring Index 75 (F-VASI75) at Week 52

    Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline).

    Time frame: 52 Weeks

  3. Incidence of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events (AEs) leading to discontinuation.

    To evaluate the safety and tolerability of ritlecitinib in adult participants with non segmental vitiligo

    Time frame: Baseline through 108 weeks

  4. Incidence of Clinically significant laboratory abnormalities.

    Time frame: Baseline through 108 weeks

Secondary outcomes

  1. Response based on F-VASI75 at 24 and 36 weeks

    Proportion of participants achieving at least a 75% improvement in F-VASI from Baseline.

    Time frame: 24 and 36 Weeks

  2. US-Only: Response based on T-VASI50 at 24 and 36 weeks

    Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline).

    Time frame: 24 and 36 weeks

  3. Global (Other than US):Patient Global Impression of Severity-Face (PGIS-F)

    To assess the effect of ritlecitinib compared to placebo on the PGIS-F at Week 24, 36 and 52

    Time frame: Week 24, 36 and week 52

  4. Global (Other than US): Patient Global Impression of Severity-Overall Vitiligo (PGIS-V)

    To assess the effect of ritlecitinib compared to placebo on the PGIS-V at Week 24, 36 and 52

    Time frame: Week 24, 36 and week 52

  5. Global (Other Than US): Response based on T-VASI50 at Week 24, 36 and 52

    Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline).

    Time frame: Week 24, 36 and 52

  6. Patient Global Impression of Change-Face (PGIC-F)

    To assess the effect of ritlecitinib compared to placebo on the PGIC-F at Weeks 36 and 52.

    Time frame: Week 36 and week 52

  7. Patient Global Impression of Change- Overall vitiligo(PGIC-V)

    To assess the effect of ritlecitinib compared to placebo on the PGIC-V at Weeks 36 and 52.

    Time frame: Week 36 and week 52

  8. Change from baseline in Dermatology Life Quality Index (DLQI)

    To evaluate the change from baseline in DLQI at week 52

    Time frame: Week 52

  9. Proportion of participants achieving disease stabilization

    The difference in the proportion of participants with stable disease at all timepoints in participants with non segmental vitiligo treated with ritlecitinib 50 mg QD and 100mg compared to placebo

    Time frame: Baseline through week 104

  10. Response based on T-VASI50

    Proportion of participants achieving T-VASI50 (defined as at least 50% improvement in T-VASI from Baseline)

    Time frame: Baseline through week 4, week 8, week 12, week 48, week 56, week 60, week 64, week 76, week 88 and week 104.

  11. Response based on F-VASI75

    Proportion of participants achieving F-VASI75 (defined as at least 75% improvement in F-VASI from Baseline)

    Time frame: Baseline through week 4, week 8, week 12, week 48, week 56, week 60, week 64, week 76, week 88 and week 104.

  12. Response based on T-VASI75

    Proportion of participants achieving T-VASI75 (defined as at least 75% improvement in T-VASI from Baseline)

    Time frame: Baseline through week 4, week 8, week 12, week 24, week 36, week 48, week 56, week 60, week 64, week 76, week 88 and week 104.

  13. Global (Other than US): Response based on T-VASI75

    Proportion of participants achieving T-VASI75 (defined as at least 75% improvement in T-VASI from Baseline)

    Time frame: Baseline through week 52

  14. Proportion of participants with sustained improvement in T-VASI

    Defined as maintenance of ≥T-VASI50 from Week 36 to Week 52

    Time frame: Week 36 through week 52

  15. Proportion of participants with sustained improvement in F-VASI

    Defined as maintenance of ≥F-VASI75 from Week 36 to 52

    Time frame: Week 36 through week 52

  16. Time to rescue medication use

    Time frame: Baseline through week 104

  17. US-Only: Percentage change from baseline (% CFB) in F-VASI at Weeks 24, 36 and 52

    To compare the efficacy of ritlecitinib 100 mg QD versus placebo on % CFB in F-VASI at Weeks 24, 36 and 52

    Time frame: Weeks 24, 36 and 52

  18. US-Only: % CFB in T-VASI at weeks 24, 36 and 52

    To compare the efficacy of ritlecitinib 100 mg QD versus placebo on % CFB in T-VASI at Weeks 24,36 and 52

    Time frame: Weeks 24, 36 and 52

  19. Response based on T-VASI90

    Proportion of participants achieving T-VASI90 (defined as at least 90% improvement in T-VASI from Baseline)

    Time frame: Baseline through week 52

  20. Response based on T-VASI100

    Proportion of participants achieving T-VASI90 (defined as at least 100% improvement in T-VASI from Baseline)

    Time frame: Baseline through week 52

  21. Response based on F-VASI50

    Proportion of participants achieving F-VASI50 (defined as at least 50% improvement in F-VASI from Baseline).

    Time frame: Baseline through week 104

  22. Change from baseline in the Hospital Anxiety and Depression Scale (HADS)

    To assess the effect of ritlecitinib compared to placebo on depression and anxiety subscales of the HADS at week 52

    Time frame: Week 52

  23. The proportion of patients achieving absence of depression on HADS depression subscale

    Response based on a 'normal' subscale score indicative of an absence of depression (in participants with baseline HADS subscale scores indicative of depression)

    Time frame: Week 52

  24. The proportion of patients achieving absence of anxiety on HADS anxiety subscale

    Response based on a 'normal' subscale score indicative of an absence of anxiety (in participants with baseline HADS subscale scores indicative of anxiety)

    Time frame: Week 52

  25. US-Only: Patient Global Impression of Severity-Face (PGIS-F)

    To assess the effect of ritlecitinib compared to placebo on the PGIS-F at 52

    Time frame: Week 52

  26. US-Only: Patient Global Impression of Severity-Overall Vitiligo (PGIS-V)

    To assess the effect of ritlecitinib compared to placebo on the PGIS-V at 52

    Time frame: Week 52

  27. % CFB in F-VASI at Week 4, 8, 12, 48, 56, 60, 64, 76, 88 and 104.

    To compare the efficacy of ritlecitinib 100 mg QD versus placebo on % CFB in F-VASI at all time points

    Time frame: Baseline through week 104

  28. % CFB in T-VASI at Week 4, 8, 12, 48, 56, 60, 64, 76, 88 and 104.

    To compare the efficacy of ritlecitinib 100 mg QD versus placebo on % CFB in T-VASI at all time points

    Time frame: Baseline through week 104

07

Study locations

229 sites

Showing the first 100 of 229 sites across 18 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Lukic T, Ghosh P, Napatalung L, Wang C, Kurosky SK, Hamzavi I, Sinclair R, Xiang L, Steil K, Rosmarin D, Parsad D, Ezzedine K, Adiri R. Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo. Dermatol Ther (Heidelb). 2026 Jul;16(7):3709-3727. doi: 10.1007/s13555-026-01724-y. Epub 2026 May 22. PubMed 42171987 ↗

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Jul 2027, 44 months after the start.

Of 18 phase 3 interventional studies under Vitiligo, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 44. This study's planned 44 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2023
First posted
Oct 10, 2023
StartActual
Nov 8, 2023
Primary completionEst.
Jul 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
40 sites added, 40 sites removed
Show 40 added (9 Bulgaria, 5 United States, 5 Spain, 4 Canada, 4 Hungary, 3 Belgium, 2 Italy, 2 Mexico, 2 Taiwan, 2 Turkey (Türkiye), 1 United Kingdom, 1 Australia)
  • Wellness Clinical Research, LLC · Hialeah, United States
  • FXM Clinical Research Miramar, LLC · Miramar, United States
  • Palmetto Clinical Trial Services, LLC · Greenville, United States
  • Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman · Liège, Belgium
  • UZ Gent · Ghent, Belgium
  • UZ Leuven · Leuven, Belgium
  • MHAT Pazardzhik · Pazardzhik, Bulgaria
  • Diagnostic Consultative Center 1 - Pernik · Pernik, Bulgaria
  • Medical Center Exacta Medica · Pleven, Bulgaria
  • Medical Center Prolet EOOD · Rousse, Bulgaria
  • Diagnostic - Consultative Center XXVIII - Sofia · Sofia, Bulgaria
  • "Diagnostic - Consultative Center XX - Sofia" EOOD · Sofia, Bulgaria
  • UMHAT "Prof. Dr. Stoyan Kirkovich"AD · Stara Zagora, Bulgaria
  • Center for Skin and Venereal Diseases - Veliko Tarnovo · Veliko Tarnovo, Bulgaria
  • Multiprofile Hospital for Active Treatment Sv. Panteleymon - Yambol AD · Yambol, Bulgaria
  • Centre de Recherche Saint-Louis (Montréal) · Montreal, Canada
  • Diex Recherche Quebec · Québec, Canada
  • Centre de Recherche Dermatologique du Quebec metropolitain · Québec, Canada
  • Alpha Recherche Clinique · Québec, Canada
  • Óbudai Egészségügyi Centrum · Budapest, Hungary
  • Trial Pharma - Semper Medical Center · Békéscsaba, Hungary
  • Orvostudomanyi Kutato es Fejleszto Kft · Debrecen, Hungary
  • Debreceni Egyetem Klinikai Kozpont · Debrecen, Hungary
  • Ospedale Civile - Azienda Ospedaliera Universitaria di Cagliari · Cagliari, Italy
  • Presidio Ospedaliero Firenze Centro Piero Palagi · Florence, Italy
  • Servicios Hospitalarios de Mexico S.A. DE C.V. · Chihuahua City, Mexico
  • Arké SMO S.A de C.V · Veracruz, Mexico
  • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
  • Clinica Universidad de Navarra · Madrid, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • …and 10 more on the registry record
Show 40 removed
  • Wellness Clinical Research · Miami Lakes, United States
  • FXM Clinical Research - Miramar · Miramar, United States
  • Palmetto Clinical Trial Services - Greenville · Greenville, United States
  • UZ Gent · Ghent, Belgium
  • UZ Leuven · Leuven, Belgium
  • Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman · Liège, Belgium
  • MHAT Pazardzhik · Pazardzhik, Bulgaria
  • Diagnostic Consultative Center 1 - Pernik · Pernik, Bulgaria
  • Medical Center Exacta Medica · Pleven, Bulgaria
  • Medical Center Prolet EOOD · Rousse, Bulgaria
  • Diagnostic - Consultative Center XXVIII - Sofia · Sofia, Bulgaria
  • "Diagnostic - Consultative Center XX - Sofia" EOOD · Sofia, Bulgaria
  • UMHAT "Prof. Dr. Stoyan Kirkovich"AD · Stara Zagora, Bulgaria
  • Center for Skin and Venereal Diseases - Veliko Tarnovo · Veliko Tarnovo, Bulgaria
  • Multiprofile Hospital for Active Treatment Sv. Panteleymon - Yambol AD · Yambol, Bulgaria
  • Centre de Recherche Saint-Louis · Montreal, Canada
  • Diex Recherche Quebec · Québec, Canada
  • Centre de Recherche Dermatologique du Quebec metropolitain · Québec, Canada
  • Alpha Recherche Clinique · Québec, Canada
  • Trial Pharma - Semper Medical Center · Békéscsaba, Hungary
  • Óbudai Egészségügyi Centrum · Budapest, Hungary
  • Orvostudomanyi Kutato es Fejleszto Kft · Debrecen, Hungary
  • Debreceni Egyetem Klinikai Kozpont · Debrecen, Hungary
  • Presidio Ospedaliero Firenze Centro Piero Palagi · Florence, Italy
  • Ospedale Civile - Azienda Ospedaliera Universitaria di Cagliari · Cagliari, Italy
  • Servicios Hospitalarios de Mexico S.A. DE C.V. · Chihuahua City, Mexico
  • Arké SMO S.A de C.V · Veracruz, Mexico
  • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
  • Clinica Universidad de Navarra · Madrid, Spain
  • Hospital Universitario 12 de Octubre · Madrid, Spain
  • …and 10 more on the registry record
across 2 updates, Oct 23, 2026 – Nov 12, 2026
Show all 2 updates
  1. Nov 12, 2026
    3 sites added, 3 sites removed
    Show 3 added (2 United States, 1 Australia)
    • Miami Dermatology and Laser Research · Miami, United States
    • Wellness Clinical Research, LLC · Miami Lakes, United States
    • Veracity Clinical Research · Greenslopes, Australia
    Show 3 removed
    • Wellness Clinical Research, LLC · Hialeah, United States
    • Miami Dermatology and Laser Institute · Miami, United States
    • Veracity Clinical Research · Woolloongabba, Australia
    + 1 other change: verification date
  2. Oct 23, 2026
    37 sites added, 37 sites removed
    Show 37 added (9 Bulgaria, 5 Spain, 4 Canada, 4 Hungary, 3 United States, 3 Belgium, 2 Italy, 2 Mexico, 2 Taiwan, 2 Turkey (Türkiye), 1 United Kingdom)
    • Wellness Clinical Research, LLC · Hialeah, United States
    • FXM Clinical Research Miramar, LLC · Miramar, United States
    • Palmetto Clinical Trial Services, LLC · Greenville, United States
    • Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman · Liège, Belgium
    • UZ Gent · Ghent, Belgium
    • UZ Leuven · Leuven, Belgium
    • MHAT Pazardzhik · Pazardzhik, Bulgaria
    • Diagnostic Consultative Center 1 - Pernik · Pernik, Bulgaria
    • Medical Center Exacta Medica · Pleven, Bulgaria
    • Medical Center Prolet EOOD · Rousse, Bulgaria
    • Diagnostic - Consultative Center XXVIII - Sofia · Sofia, Bulgaria
    • "Diagnostic - Consultative Center XX - Sofia" EOOD · Sofia, Bulgaria
    • UMHAT "Prof. Dr. Stoyan Kirkovich"AD · Stara Zagora, Bulgaria
    • Center for Skin and Venereal Diseases - Veliko Tarnovo · Veliko Tarnovo, Bulgaria
    • Multiprofile Hospital for Active Treatment Sv. Panteleymon - Yambol AD · Yambol, Bulgaria
    • Centre de Recherche Saint-Louis (Montréal) · Montreal, Canada
    • Diex Recherche Quebec · Québec, Canada
    • Centre de Recherche Dermatologique du Quebec metropolitain · Québec, Canada
    • Alpha Recherche Clinique · Québec, Canada
    • Óbudai Egészségügyi Centrum · Budapest, Hungary
    • Trial Pharma - Semper Medical Center · Békéscsaba, Hungary
    • Orvostudomanyi Kutato es Fejleszto Kft · Debrecen, Hungary
    • Debreceni Egyetem Klinikai Kozpont · Debrecen, Hungary
    • Ospedale Civile - Azienda Ospedaliera Universitaria di Cagliari · Cagliari, Italy
    • Presidio Ospedaliero Firenze Centro Piero Palagi · Florence, Italy
    • Servicios Hospitalarios de Mexico S.A. DE C.V. · Chihuahua City, Mexico
    • Arké SMO S.A de C.V · Veracruz, Mexico
    • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
    • Clinica Universidad de Navarra · Madrid, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • …and 7 more on the registry record
    Show 37 removed
    • Wellness Clinical Research · Miami Lakes, United States
    • FXM Clinical Research - Miramar · Miramar, United States
    • Palmetto Clinical Trial Services - Greenville · Greenville, United States
    • UZ Gent · Ghent, Belgium
    • UZ Leuven · Leuven, Belgium
    • Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman · Liège, Belgium
    • MHAT Pazardzhik · Pazardzhik, Bulgaria
    • Diagnostic Consultative Center 1 - Pernik · Pernik, Bulgaria
    • Medical Center Exacta Medica · Pleven, Bulgaria
    • Medical Center Prolet EOOD · Rousse, Bulgaria
    • Diagnostic - Consultative Center XXVIII - Sofia · Sofia, Bulgaria
    • "Diagnostic - Consultative Center XX - Sofia" EOOD · Sofia, Bulgaria
    • UMHAT "Prof. Dr. Stoyan Kirkovich"AD · Stara Zagora, Bulgaria
    • Center for Skin and Venereal Diseases - Veliko Tarnovo · Veliko Tarnovo, Bulgaria
    • Multiprofile Hospital for Active Treatment Sv. Panteleymon - Yambol AD · Yambol, Bulgaria
    • Centre de Recherche Saint-Louis · Montreal, Canada
    • Diex Recherche Quebec · Québec, Canada
    • Centre de Recherche Dermatologique du Quebec metropolitain · Québec, Canada
    • Alpha Recherche Clinique · Québec, Canada
    • Trial Pharma - Semper Medical Center · Békéscsaba, Hungary
    • Óbudai Egészségügyi Centrum · Budapest, Hungary
    • Orvostudomanyi Kutato es Fejleszto Kft · Debrecen, Hungary
    • Debreceni Egyetem Klinikai Kozpont · Debrecen, Hungary
    • Presidio Ospedaliero Firenze Centro Piero Palagi · Florence, Italy
    • Ospedale Civile - Azienda Ospedaliera Universitaria di Cagliari · Cagliari, Italy
    • Servicios Hospitalarios de Mexico S.A. DE C.V. · Chihuahua City, Mexico
    • Arké SMO S.A de C.V · Veracruz, Mexico
    • Hospital de la Santa Creu i Sant Pau · Barcelona, Spain
    • Clinica Universidad de Navarra · Madrid, Spain
    • Hospital Universitario 12 de Octubre · Madrid, Spain
    • …and 7 more on the registry record
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06072183
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Oct 10, 2023
Start date
Nov 8, 2023
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-06651600

Start the discussion